NurOwn, phase 2, randomized, clinical trial in patients with ALS: Safety, clinical, and biomarker results

OBJECTIVE: To determine the safety and efficacy of mesenchymal stem cell (MSC)-neurotrophic factor (NTF) cells (NurOwn®, autologous bone marrow-derived MSCs, induced to secrete NTFs) delivered by combined intrathecal and intramuscular administration to participants with amyotrophic lateral sclerosis...

Descripción completa

Detalles Bibliográficos
Autores principales: Berry, James D., Cudkowicz, Merit E., Windebank, Anthony J., Staff, Nathan P., Owegi, Margaret, Nicholson, Katherine, McKenna-Yasek, Diane, Levy, Yossef S., Abramov, Natalie, Kaspi, Haggai, Mehra, Munish, Aricha, Revital, Gothelf, Yael, Brown, Robert H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937497/
https://www.ncbi.nlm.nih.gov/pubmed/31740545
http://dx.doi.org/10.1212/WNL.0000000000008620

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937497/
https://www.ncbi.nlm.nih.gov/pubmed/31740545
http://dx.doi.org/10.1212/WNL.0000000000008620

Ejemplares similares